Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
Original title: “FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns”
Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.
Original title: “Star adds $200M after spinout successes”
EMA’s Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely start of clinical trials for potential…
Original title: “AMA and EMA issue joint guidance on Ebola vaccine development”
Read twice and referred to the Committee on the Judiciary.
Original title: “S 1837: Law Enforcement Training for Mental Health Crisis Response Act of 2021”
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Original title: “HR 3595: Law Enforcement Training for Mental Health Crisis Response Act of 2021”
remibrutinib versus teriflunomide in relapsing multiple sclerosis remodel 1 and remodel 2 two randomised phase 3 trials
Original title: “Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.”
functional stratification of ywhaz variants explains distinct neurodevelopmental disorders
Original title: “Functional stratification of YWHAZ variants explains distinct neurodevelopmental disorders.”